Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency
Understanding patient and caregiver preferences for LA-GHA devices with less injection pain and greater ease of use highlights the value of shared decision-making, potentially leading to better treatment adherence and subsequent clinical outcomes.
Authors
- Bradley S. Miller (ORCID: https://orcid.org/0000-0003-3663-5473)
- Jing Voon Chen (ORCID: https://orcid.org/0000-0003-3632-6806)
- Brad Mason
- Clare Kennedy
- Graceanne Wayser
- Nicky Kelepouris
- Kevin C J Yuen
Institutions
- Creighton University (US)
- Fairview Health Services (US)
- Barrow Neurological Institute (US)
- University of Arizona (US)
- Adelphi Group (United Kingdom) (GB)
- Novo Nordisk (United States) (US)
- University of Minnesota Medical Center (US)
- Adelphi Laboratory Center (US)
Publication Details
- Journal
- Journal of the Endocrine Society
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1210/jendso/bvaf219
- Citations
- 1
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Novo Nordisk
- Ipsen